Epigenetic regulation of cell life and death decisions and deregulation in cancer

Essays in Biochemistry

Volumn 48, Issue , 2010, Pages 121-146

  Hajji, Nabil ^a   Joseph, Bertrand ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; APOPTOSIS; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; REVIEW; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS;

EID: 79952110842     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/BSE0480121     Document Type: Article

References (126)

1. Zhivotovsky, B., Joseph, B. and Orrenius, S. (1999) Tumor radiosensitivity and apoptosis. Exp. Cell Res. 248, 10-17
2. Henry-Mowatt, J., Dive, C., Martinou, J.C. and James, D. (2004) Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 23, 2850-2860
3. Zou, H., Li, Y., Liu, X. and Wang, X. (1999) An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274, 11549-11556
4. Coultas, L. and Strasser, A. (2003) The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 13, 115-123
5. Martinou, J.C. and Green, D.R. (2001) Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2, 63-67
6. Willis, S.N. and Adams, J.M. (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617-625
7. Jourdain, A. and Martinou, J.C. (2009) Mitochondrial outer-membrane permeabilization and remodelling in apoptosis. Int. J. Biochem. Cell Biol. 41, 1884-1889
8. Yee, K.S. and Vousden, K.H. (2005) Complicating the complexity of p53. Carcinogenesis 26, 1317-1322
9. Debatin, K.M. and Krammer, P.H. (2004) Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966
10. Chinnaiyan, A.M., O'Rourke, K., Tewari, M. and Dixit, V.M. (1995) FADD, a novel death domaincontaining protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505-512
11. Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P.H. and Peter, M.E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588
12. Ashkenazi, A. (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discovery 7, 1001-1012
13. Barnhart, B.C., Alappat, E.C. and Peter, M.E. (2003) The CD95 type I/type II model. Semin. Immunol. 15, 185-193
14. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R. et al. (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16, 3-11
15. Fraga, M.F., Ballestar, E., Paz, M.F., Ropero, S., Setien, F., Ballestar, M.L., Heine-Suner, D., Cigudosa, J.C., Urioste, M., Benitez, J. et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U.S.A. 102, 10604-10609
16. Humpherys, D., Eggan, K., Akutsu, H., Hochedlinger, K., Rideout, 3rd, W.M., Biniszkiewicz, D., Yanagimachi, R. and Jaenisch, R. (2001) Epigenetic instability in ES cells and cloned mice. Science 293, 95-97
17. Waddington, C.H. (1939) Preliminary notes on the development of the wings in normal and mutant strains of Drosophila. Proc. Natl. Acad. Sci. U.S.A. 25, 299-307
18. Holliday, R. (1987) The inheritance of epigenetic defects. Science 238, 163-170
19. Feinberg, A.P. and Vogelstein, B. (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92
20. Baylin, S.B. and Ohm, J.E. (2006) Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116
21. Petak, I., Danam, R.P., Tillman, D.M., Vernes, R., Howell, S.R., Berczi, L., Kopper, L., Brent, T.P. and Houghton, J.A. (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ. 10, 211-217
22. van Noesel, M.M., van Bezouw, S., Salomons, G.S., Voute, P.A., Pieters, R., Baylin, S.B., Herman, J.G. and Versteeg, R. (2002) Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 62, 2157-2161
23. Shivapurkar, N., Toyooka, S., Toyooka, K.O., Reddy, J., Miyajima, K., Suzuki, M., Shigematsu, H., Takahashi, T., Parikh, G., Pass, H.I. et al. (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer 109, 786-792
24. Margetts, C.D., Astuti, D., Gentle, D.C., Cooper, W.N., Cascon, A., Catchpoole, D., Robledo, M., Neumann, H.P., Latif, F. and Maher, E.R. (2005) Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocr. Relat. Cancer 12, 161-172
25. Elias, A., Siegelin, M.D., Steinmuller, A., von Deimling, A., Lass, U., Korn, B. and Mueller, W. (2009) Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosisinducing ligand resistance in gliomas. Clin. Cancer Res. 15, 5457-5465
26. Jin, Y. and Gallagher, P.J. (2003) Antisense depletion of death-associated protein kinase promotes apoptosis. J. Biol. Chem. 278, 51587-51593
27. Raveh, T., Droguett, G., Horwitz, M.S., DePinho, R.A. and Kimchi, A. (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat. Cell Biol. 3, 1-7
28. Kissil, J.L., Feinstein, E., Cohen, O., Jones, P.A., Tsai, Y.C., Knowles, M.A., Eydmann, M.E. and Kimchi, A. (1997) DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene 15, 403-407
29. Lain, S. and Lane, D. (2003) Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer 39, 1053-1060
30. Agirre, X., Vizmanos, J.L., Calasanz, M.J., Garcia-Delgado, M., Larrayoz, M.J. and Novo, F.J. (2003) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 22, 1070-1072
31. San Jose-Eneriz, E., Agirre, X., Jimenez-Velasco, A., Cordeu, L., Martin, V., Arqueros, V., Garate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J.A. et al. (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur. J. Cancer 45, 1877-1889
32. Schroeder, M. and Mass, M.J. (1997) CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem. Biophys. Res. Commun. 235, 403-406
33. Wales, M.M., Biel, M.A., el Deiry, W., Nelkin, B.D., Issa, J.P., Cavenee, W.K., Kuerbitz, S.J. and Baylin, S.B. (1995) p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1, 570-577
34. Chen, W.Y., Wang, D.H., Yen, R.C., Luo, J., Gu, W. and Baylin, S.B. (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437-448
35. Cook, J.R., Lee, J.H., Yang, Z.H., Krause, C.D., Herth, N., Hoffmann, R. and Pestka, S. (2006) FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem. Biophys. Res. Commun. 342, 472-481
36. Soengas, M.S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J.G., Gerald, W.L., Lazebnik, Y.A. et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211
37. Fu, W.N., Bertoni, F., Kelsey, S.M., McElwaine, S.M., Cotter, F.E., Newland, A.C. and Jia, L. (2003) Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 22, 451-455
38. Furukawa, Y., Sutheesophon, K., Wada, T., Nishimura, M., Saito, Y., Ishii, H. and Furukawa, Y. (2005) Methylation silencing of the Apaf-1 gene in acute leukemia. Mol. Cancer Res. 3, 325-334
39. Wang, H.L., Bai, H., Li, Y., Sun, J. and Wang, X.Q. (2007) Rationales for expression and altered expression of apoptotic protease activating factor-1 gene in gastric cancer. World J. Gastroenterol. 13, 5060-5064
40. Christoph, F., Kempkensteffen, C., Weikert, S., Kollermann, J., Krause, H., Miller, K., Schostak, M. and Schrader, M. (2006) Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer 95, 1701-1707
41. Byun, D.S., Cho, K., Ryu, B.K., Lee, M.G., Kang, M.J., Kim, H.R. and Chi, S.G. (2003) Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 63, 7068-7075
42. Tu, S.P., Liston, P., Cui, J.T., Lin, M.C., Jiang, X.H., Yang, Y., Gu, Q., Jiang, S.H., Lum, C.T., Kung, H.F. et al. (2009) Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int. J. Cancer 125, 688-697
43. Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F. and Richmond, T.J. (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389, 251-260
44. Khorasanizadeh, S. (2004) The nucleosome: from genomic organization to genomic regulation. Cell 116, 259-272
45. Cosgrove, M.S., Boeke, J.D. and Wolberger, C. (2004) Regulated nucleosome mobility and the histone code. Nat. Struct. Mol. Biol. 11, 1037-1043
46. Rundlett, S.E., Carmen, A.A., Suka, N., Turner, B.M. and Grunstein, M. (1998) Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 392, 831-835
47. Vogelauer, M., Wu, J., Suka, N. and Grunstein, M. (2000) Global histone acetylation and deacetylation in yeast. Nature 408, 495-498
48. Strahl, B.D., Ohba, R., Cook, R.G. and Allis, C.D. (1999) Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc. Natl. Acad. Sci. U.S.A. 96, 14967-14972
49. Horn, P.J. and Peterson, C.L. (2006) Heterochromatin assembly: a new twist on an old model. Chromosome Res. 14, 83-94
50. Shukla, A., Chaurasia, P. and Bhaumik, S.R. (2009) Histone methylation and ubiquitination with their cross-talk and roles in gene expression and stability. Cell Mol. Life Sci. 66, 1419-1433
51. Sengupta, N. and Seto, E. (2004) Regulation of histone deacetylase activities. J. Cell. Biochem. 93, 57-67
52. Dillon, S.C., Zhang, X., Trievel, R.C. and Cheng, X. (2005) The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6, 227
53. McBride, A.E. and Silver, P.A. (2001) State of the arg: protein methylation at arginine comes of age. Cell 106, 5-8
54. Bannister, A.J., Schneider, R. and Kouzarides, T. (2002) Histone methylation: dynamic or static? Cell 109, 801-806
55. .Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero, R.A. and Shi, Y. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953
56. Nakashima, K., Hagiwara, T. and Yamada, M. (2002) Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J. Biol. Chem. 277, 49562-49568
57. Cuthbert, G.L., Daujat, S., Snowden, A.W., Erdjument-Bromage, H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P.D., Tempst, P., Bannister, A.J. and Kouzarides, T. (2004) Histone deimination antagonizes arginine methylation. Cell 118, 545-553
58. Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298
59. Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K. et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391-400
60. Seligson, D.B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M. and Kurdistani, S.K. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266
61. Fahrner, J.A., Eguchi, S., Herman, J.G. and Baylin, S.B. (2002) Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62, 7213-7218
62. Ballestar, E., Paz, M.F., Valle, L., Wei, S., Fraga, M.F., Espada, J., Cigudosa, J.C., Huang, T.H. and Esteller, M. (2003) Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22, 6335-6345
63. Richon, V.M., Sandhoff, T.W., Rifkind, R.A. and Marks, P.A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97, 10014-10019
64. Ozdag, H., Teschendorff, A.E., Ahmed, A.A., Hyland, S.J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M.J. et al. (2006) Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7, 90
65. Gibbons, R.J. (2005) Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum. Mol. Genet. 14 (Spec No 1), R85-R92
66. Pfister, S., Rea, S., Taipale, M., Mendrzyk, F., Straub, B., Ittrich, C., Thuerigen, O., Sinn, H.P., Akhtar, A. and Lichter, P. (2008) The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int. J. Cancer 122, 1207-1213
67. Yang, X.J. (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32, 959-976
68. Moore, S.D., Herrick, S.R., Ince, T.A., Kleinman, M.S., Dal Cin, P., Morton, C.C. and Quade, B.J. (2004) Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res. 64, 5570-5577
69. Ropero, S. and Esteller, M. (2007) The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 1, 19-25
70. Albert, M. and Helin, K. (2010) Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 21, 209-220
71. Kampranis, S.C. and Tsichlis, P.N. (2009) Histone demethylases and cancer. Adv. Cancer Res. 102, 103-169
72. Talasz, H., Helliger, W., Puschendorf, B. and Lindner, H. (1996) In vivo phosphorylation of histone H1 variants during the cell cycle. Biochemistry 35, 1761-1767
73. Soloaga, A., Thomson, S., Wiggin, G.R., Rampersaud, N., Dyson, M.H., Hazzalin, C.A., Mahadevan, L.C. and Arthur, J.S. (2003) MSK2 and MSK1 mediate the mitogen-and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 22, 2788-2797
74. Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Adeogun, A.O., Nakayama, T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend, A. et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262-267
75. Vermeulen, L., Berghe, W.V., Beck, I.M., De Bosscher, K. and Haegeman, G. (2009) The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 34, 311-318
76. Ajiro, K. (2000) Histone H2B phosphorylation in mammalian apoptotic cells. An association with DNA fragmentation. J. Biol. Chem. 275, 439-443
77. Cheung, W.L., Ajiro, K., Samejima, K., Kloc, M., Cheung, P., Mizzen, C.A., Beeser, A., Etkin, L.D., Chernoff, J., Earnshaw, W.C. and Allis, C.D. (2003) Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113, 507-517
78. van Bavel, C.C., Dieker, J., Muller, S., Briand, J.P., Monestier, M., Berden, J.H. and van der Vlag, J. (2009) Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol. Immunol. 47, 511-516
79. Fernandez-Capetillo, O., Allis, C.D. and Nussenzweig, A. (2004) Phosphorylation of histone H2B at DNA double-strand breaks. J. Exp. Med. 199, 1671-1677
80. Solier, S., Sordet, O., Kohn, K.W. and Pommier, Y. (2009) Death receptor-induced activation of the Chk2-and histone H2AX-associated DNA damage response pathways. Mol. Cell. Biol. 29, 68-82
81. Solier, S. and Pommier, Y. (2009) The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 8, 1853-1859
82. Talasz, H., Helliger, W., Sarg, B., Debbage, P.L., Puschendorf, B. and Lindner, H. (2002) Hyperphosphorylation of histone H2A.X and dephosphorylation of histone H1 subtypes in the course of apoptosis. Cell Death Differ. 9, 27-39
83. Cook, P.J., Ju, B.G., Telese, F., Wang, X., Glass, C.K. and Rosenfeld, M.G. (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458, 591-596
84. Stucki, M. (2009) Histone H2A.X Tyr142 phosphorylation: a novel sWItCH for apoptosis? DNA Repair (Amst) 8, 873-876
85. Kondo, Y., Shen, L., Cheng, A.S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi-Addo, B. et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741-750
86. Feng, Y., Wang, X., Xu, L., Pan, H., Zhu, S., Liang, Q., Huang, B. and Lu, J. (2009) The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. FEBS J. 276, 4197-4206
87. Yang, X., Karuturi, R.K., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L.D., Tan, P.B. and Yu, Q. (2009) CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4, e5011
88. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297
89. Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A. et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834-838
90. Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y. et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753-3756
91. Coller, H.A., Forman, J.J. and Legesse-Miller, A. (2007) 'Myc'ed messages': myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet 3, e146
92. Chan, J.A., Krichevsky, A.M. and Kosik, K.S. (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029-6033
93. Cheng, A.M., Byrom, M.W., Shelton, J. and Ford, L.P. (2005) Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33, 1290-1297
94. Ermoian, R.P., Furniss, C.S., Lamborn, K.R., Basila, D., Berger, M.S., Gottschalk, A.R., Nicholas, M.K., Stokoe, D. and Haas-Kogan, D.A. (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100-1106
95. Frankel, L.B., Christoffersen, N.R., Jacobsen, A., Lindow, M., Krogh, A. and Lund, A.H. (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283, 1026-1033
96. Shen, X.H., Han, Y.J., Zhang, D.X., Cui, X.S. and Kim, N.H. (2009) A link between the interleukin-6/Stat3 anti-apoptotic pathway and microRNA-21 in preimplantation mouse embryos. Mol. Reprod. Dev. 76, 854-862
97. Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., Wojcik, S.E., Aqeilan, R.I., Zupo, S., Dono, M. et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A. 102, 13944-13949
98. He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D. et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134
99. Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z. and Oren, M. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell. 26, 731-743
100. Wang, Y. and Lee, C.G. (2009) MicroRNA and cancer-focus on apoptosis. J. Cell Mol. Med. 13, 12-23
101. Szyf, M. (2008) The role of DNA hypermethylation and demethylation in cancer and cancer therapy. Curr. Oncol. 15, 72-75
102. Marks, P.A. and Dokmanovic, M. (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497-1511
103. Camphausen, K. and Tofilon, P.J. (2007) Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25, 4051-4056
104. Hajji, N., Wallenborg, K., Vlachos, P., Nyman, U., Hermanson, O. and Joseph, B. (2008) Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 27, 3134-3144
105. Kristensen, L.S., Nielsen, H.M. and Hansen, L.L. (2009) Epigenetics and cancer treatment. Eur. J. Pharmacol. 625, 131-142
106. Stimson, L., Wood, V., Khan, O., Fotheringham, S. and La Thangue, N.B. (2009) HDAC inhibitorbased therapies and haematological malignancy. Ann. Oncol. 20, 1293-1302
107. Huang, Y., Marton, L.J., Woster, P.M. and Casero, R.A. (2009) Polyamine analogues targeting epigenetic gene regulation. Essays Biochem. 46, 95-110
108. Yang, B.F., Lu, Y.J. and Wang, Z.G. (2009) MicroRNAs and apoptosis: implications in the molecular therapy of human disease. Clin. Exp. Pharmacol. Physiol. 36, 951-960
109. Casalini, P. and Iorio, M.V. (2009) MicroRNAs and future therapeutic applications in cancer. J. Buon. 14 (Suppl 1), S17-S22
110. Saito, Y., Suzuki, H., Tsugawa, H., Nakagawa, I., Matsuzaki, J., Kanai, Y. and Hibi, T. (2009) Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28, 2738-2744
111. Xu, J., Liao, X. and Wong, C. (2009) Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int. J. Cancer. 126, 1029-1035
112. Crawford, M., Batte, K., Yu, L., Wu, X., Nuovo, G.J., Marsh, C.B., Otterson, G.A. and Nana-Sinkam, S.P. (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem. Biophys. Res. Commun. 388, 483-489
113. Wang, Y., Yu, Q., Cho, A.H., Rondeau, G., Welsh, J., Adamson, E., Mercola, D. and McClelland, M. (2005) Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7, 748-760
114. Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., Desano, J.T., Bommer, G.T., Fan, D. et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4, e6816
115. Kempkensteffen, C., Hinz, S., Schrader, M., Christoph, F., Magheli, A., Krause, H., Schostak, M., Miller, K. and Weikert, S. (2007) Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. Cancer Lett. 254, 227-235
116. Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E. and Monzo, M. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114, 2945-2951
117. Aguilera, D.G., Das, C.M., Sinnappah-Kang, N.D., Joyce, C., Taylor, P.H., Wen, S., Hasselblatt, M., Paulus, W., Fuller, G., Wolff, J.E. and Gopalakrishnan, V. (2009) Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J. Neurooncol. 93, 303-318
118. Lu, Q., Lu, C., Zhou, G.P., Zhang, W., Xiao, H. and Wang, X.R. (2010) MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol. Oncol., doi:10.1016/jurlonc.2009.06.005
119. Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J.L., Matta, H., Miyajima, K., Timmons, C.F., Tomlinson, G.E., Mastrangelo, D. et al. (2002) Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 62, 5897-5901
120. Pompeia, C., Hodge, D.R., Plass, C., Wu, Y.Z., Marquez, V.E., Kelley, J.A. and Farrar, W.L. (2004) Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res. 64, 3465-3473
121. Myzak, M.C., Dashwood, W.M., Orner, G.A., Ho, E. and Dashwood, R.H. (2006) Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 20, 506-508
122. Zenz, T., Mohr, J., Eldering, E., Kater, A.P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van Oers, M.H.J., Mertens, D. et al. (2009) miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113, 3801-3808
123. Zhang, C.Z., Kang, C.S., Pu, P.Y., Wang, G.X., Jia, Z.F., Zhang, A.L., Han, L. and Xu, P. (2009) [Inhibitory effect of knocking down microRNA-221 and microRNA-222 on glioma cell growth in vitro and in vivo]. Zhonghua Zhong Liu Za Zhi 31, 721-726
124. Paschos, K., Smith, P., Anderton, E., Middeldorp, J.M., White, R.E. and Allday, M.J. (2009) Epsteinbarr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog. 5, e1000492
125. Ji, Q., Hao, X.B., Meng, Y., Zhang, M., DeSano, J., Fan, D.M. and Xu, L. (2008) Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8, 266
126. Agirre, X., Novo, F.J., Calasanz, M.J., Larrayoz, M.J., Lahortiga, I., Valganon, M., Garcia-Delgado, M. and Vizmanos, J.L. (2003) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol. Carcinogenesis 38, 201-208